Form 4: Neurocrine Biosciences Director Shalini Sharp Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Shalini Sharp exercised stock options and sold shares of Neurocrine Biosciences (NBIX) under a pre-arranged 10b5-1 trading plan.

Summary

• On May 17, 2024, Shalini Sharp, a director of Neurocrine Biosciences Inc. (NBIX), executed a transaction involving the company's common stock.
• Sharp acquired 2,100 shares of common stock through the exercise of restricted stock units (RSUs).
• Simultaneously, Sharp sold 1,106 shares of common stock at a weighted average price of $141.9018 per share, with individual sales prices ranging from $140.81 to $142.33.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2023.
• Following these transactions, Sharp directly owns 994 shares of Neurocrine Biosciences common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the director's confidence in the company.

Industry Context

Insider transactions are common and closely monitored, especially in the pharmaceutical industry, to ensure compliance with regulations and to provide transparency to investors.

Comparison to Industry Standards

• Transactions under 10b5-1 plans are a common practice among corporate insiders to avoid accusations of trading on non-public information.
• The volume of shares sold is relatively small compared to the overall trading volume of NBIX, suggesting a limited impact on the stock price.
• Comparing Sharp's transactions to those of other directors in similar biotech companies could provide further context, but that data is not available in this document.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider activity.
• The impact on employees, customers, suppliers, and creditors is likely minimal.

Key Dates